Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success.
uniQure: Two Upgrades, One Regulatory Shift
The most dramatic call belongs to uniQure. RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is “not inconceivable” that the FDA reverts to its prior stance, and believes Prasad’s departure is likely to open up a more balanced discussion on risk/reward for Huntington’s disease. RBC now places a 50% chance the drug ultimately gets approved.
The clinical data underpinning that view is meaningful. AMT-130’s Phase I/II 36-month data showed statistically significant 75% slowing in disease progression on cUHDRS (p=0.003) and 60% slowing on TFC (p=0.033). The FDA’s January 2026 directive requires a full randomized, double-blind, sham surgery-controlled Phase III trial before any marketing application, and uniQure has a Type B meeting with the FDA planned for Q2 2026 to discuss Phase III study design.
The stock currently trades at $16.52, well below both price targets. The consensus analyst target sits at $28.45, with 10 buy ratings and 3 holds across the coverage universe. The stock has surged 53.33% over the past week as the upgrade cycle took hold, though it remains down 32.72% year-to-date from its January levels. The binary nature of an FDA outcome remains a key consideration. uniQure does hold $622.5M in cash with runway into H2 2029, limiting near-term dilution risk.
Syndax: IPF Optionality Not in the Price
JPMorgan’s call on Syndax is more straightforward. The firm raised its price target to $45 from $33 and kept an Overweight rating. The core argument: at current share levels, no value is being ascribed to the Niktimvo IPF opportunity, with Phase 2 MAXPIRe data expected in Q4 2026. JPMorgan sees the value of Revuforj and Niktimvo in the refractory commercial setting alone in the high-$20s to low-$30s per share range.
Syndax trades at $23.23 against a consensus target of $38.09, with 12 buy ratings and zero sells across coverage. The commercial trajectory supports the bullish read: Revuforj posted Q4 net revenue of $44.20M, up 38% sequentially, with total prescriptions of approximately 1,150, up 35% quarter-over-quarter. Management has guided toward profitability without additional capital raises, adding credibility to the JPMorgan thesis.
Erasca: Catalyst Watch on a RAS Inhibitor
JPMorgan added Erasca to its “Positive Catalyst Watch list” ahead of the initial Phase 1 AURORAS-1 readout for ERAS-0015 in RAS-mutant solid tumors, expected in the first half of 2026. The firm sees a high probability of an upside scenario and “multiple ways to win” in the initial update, with share upside into the high-teens to high-$20s in win scenarios. JPMorgan keeps an Overweight rating and established a year-end 2026 price target of $24.
Erasca trades at $15.20, already up 305.17% year-to-date. The stock has moved sharply ahead of the readout, compressing some of the upside implied by JPMorgan’s $24 target. The consensus target of $11.56 sits below the current price, though that figure likely reflects stale ratings predating the recent run. ERAS-0015 carries a U.S. composition of matter patent through September 2043, providing long-duration IP protection if the asset proves out clinically.
Across all three names, the analyst signal is directionally consistent: the market is underpricing catalyst optionality. Each name carries meaningful binary risk tied to upcoming clinical and regulatory readouts.
Top Gaining Stocks
Top Losing Stocks